Drug Proposed CZE method Reference method       Ref. [2]
  NLB®Nalufin
50- 200 µg mL-1		 Taken
µg mL-1		 Found
µg mL-1		 %
Recovery		 Taken
µg mL-1		 Found
µg mL-1		 %
Recovery
50
100
140
160
180
200		 49.15
99.82
139.36
159.12
179.75
199.32		 98.30
99.82
99.54
99.37
99.86
99.66		 2
4
6
8
10
15		 2.00
3.96
5.87
8.00
9.96
14.99		 100.0
99.0
97.8
100.0
99.6
99.9
Mean ± SD
n
Variance
%SE
t-test
F-test		 99.43 ± 0.5
6
0.25
0.20
0.129(2.228)*
2.56(5.05)*		 99.38 ± 0.8
6
0.64
0.33
  NLX®Narcan
100-240 µg mL-1		 100
140
160
180
200
240		 98.35
139.12
158.53
179.76
199.45
239.47		 98.35
99.37
99.08
99.87
99.73
99.78		 10
20
40
60
80
100		 9.99
19.89
39.95
59.85
79.99
98.58		 99.9
99.5
99.9
99.8
99.9
98.6		     Ref [10]
Mean ± SD
n
Variance
%SE
t-test
F-test		 99.36 ± 0.6
6
0.36
0.24
0.768(2.228)*
1.44(5.05)*		 99.60 ± 0.5
6
0.25
0.20
  NLT®Vivitrol
50-280 µg mL-1		 50
100
150
200
240
280		 49.95
99.14
149.69
200.00
239.36
279.47		 99.90
99.14
99.79
100.00
99.73
99.81		 12
16
20
24
28
32		 11.95
15.89
20.00
23.78
27.94
31.95		 99.6
99.3
100.0
99.0
99.8
99.8		     Ref [21]
Mean ± SD
n
Variance
%SE
t-test
F-test		 99.73 ± 0.3
6
0.09
0.12
0.750(2.228)*
1.78(5.05)*		 99.58 ± 0.4
6
0.16
0.16
* Figures in parentheses are the tabulated values of t-and F- testes at 95% confidence limit [32]** %SE= SD/image
Table 6: Analytical results of the determination of NLB, NLX and NLT in dosage forms using CZE method and reference methods.